A First-ever Research Collaboration to Characterize MRI Measured Neural Flexibility Development in Chinese Toddlers (MIND)

October 2, 2023 updated by: Société des Produits Nestlé (SPN)
The overall objective is to characterize the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, in Chinese toddlers (32 to 42 months old).

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

The primary objective of this clinical study is to characterize in Chinese toddlers ages 32 - 42 months old the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, and to assess a range of executive functions (inhibit, shift, emotional control, working memory, plan/organize) using the Global Executive Composite summary score obtained from the BRIEF-P standardized rating scale.

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shanghai
      • Shanghai, Shanghai, China
        • Shanghai Children's Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 1 year (Child)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Healthy normal developing Chinese toddlers; minimum number of subjects with successful MRI scans at enrolment and age 42 months: N=60 (≈ 30 fed on S-26 GOLD/ ULTIMA growing-up milk (GUM) and ≈30 fed on cows' milk) with key inclusion as daily consumption of the S-26 GUM or cow's milk for the last 60 days (2 mo).

Description

Inclusion Criteria:

  1. Written informed consent has been obtained from the parent/legally acceptable representative.
  2. Full-term birth (more than 37 weeks and >2.5kg)
  3. Children aged between 32 to 34 mo or 2.8 to 2.10 years at enrollment
  4. Neurotypical development as assessed by interview
  5. No major risk factors for learning, neurologic, or psychiatric disorder as assessed by interview [defined as a diagnosed learning neurologic or psychiatric disorder in a first degree relative (e.g. parents, siblings)].
  6. Dietary requirement detailed below:

S-26 GOLD or ULTIMA GUM--fed group:

I. Daily consumption of S-26 GOLD or ULTIMA GUM for the last 60 days (2 months) II. Desire of the parent to continue feeding GUM during the course of the study

Cow's milk-fed group:

I. Daily consumption of cow's milk or for the last 60 days (2 months) II. Desire of the parent to continue feeding cow's milk during the course of the study

Exclusion Criteria:

  1. Delayed birth ( > 41 weeks gestation) as reported in medical record
  2. Birth Weight < 2500 g or small for gestational age (birth weight below the 10th percentile) or large for gestational age (birth weight above the 90th percentile) as reported in medical record
  3. History of neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in the toddler as assessed by interview
  4. History of diagnosed neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in parents or siblings, as assessed by interview
  5. In utero exposure to alcohol abuse or illicit substances as defined as diagnosis of current substance use disorder in the biological mother and guidelines set by the American College of Obstetricians and Gynecologists and the Royal College of Physicians
  6. Multiple birth as reported in medical record
  7. Complicated pregnancy (e.g., preeclampsia, gestational diabetes) as assessed by medical interview/ medical record
  8. Abnormal screening laboratory values and studies considered to be clinically significant in the opinion of the Investigator (e.g., metabolic disease screening, neonatal bilirubin)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
S-26 GOLD/ULTIMA GUM-fed group:

Parent(s) to continue feeding their child S-26 GOLD or ULTIMA GUM during the course of the study.

We will collect information from parents on the S-26 GOLD/ ULTIMA GUM for a maximum of 2 months prior to the study start and during the course of the study.

MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).
Cow's milk-fed group:

Parent(s) to continue feeding their child cow's milk during the course of the study.

We will collect information from parents on the cow's milk consumed for a maximum of 2 months prior to the study start and during the course of the study.

MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neural flexibility
Time Frame: at baseline and 8 months after baseline
Neural flexibility is a quantitative measure of the frequency at which brain regions change their allegiance from one functional module to another during a given time period. It will be measured by MRI at the brain regions implicated to be associated with cognitive flexibility (including anterior cingulate cortex, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, anterior insula, interior frontal junction, superior parietal lobule, precuneus, intraparietal sulcus, frontal eye fields, and temporoparietal junction)
at baseline and 8 months after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brain structure (brain regions volume)
Time Frame: at baseline and 8 months after baseline
Brain structure (brain regions volume) measured using MRI, including the hippocampal and frontal lobe volume (in cubic millimeter)
at baseline and 8 months after baseline
Brain structure (cortical surface area)
Time Frame: at baseline and 8 months after baseline
Brain structure (cortical surface area) measured using MRI
at baseline and 8 months after baseline
Brain structure (cortical thickness)
Time Frame: at baseline and 8 months after baseline
Brain structure (cortical thickness) measured using MRI
at baseline and 8 months after baseline
Brain structure (myelination)
Time Frame: at baseline and 8 months after baseline
Brain structure (myelination) measured using MRI
at baseline and 8 months after baseline
Brain function (network topologies)
Time Frame: at baseline and 8 months after baseline
Brain functional network topologies of the nine commonly assessed brain functional networks, including the primary visual, secondary visual, visual association, motosensory, default mode, frontoparietal, medial frontal, subcortical and cerebellum networks using MRI
at baseline and 8 months after baseline
Brain function (connection strengths)
Time Frame: at baseline and 8 months after baseline
Brain functional connection strengths of the nine commonly assessed brain functional networks, including the primary visual, secondary visual, visual association, motosensory, default mode, frontoparietal, medial frontal, subcortical and cerebellum networks using MRI
at baseline and 8 months after baseline
Children development
Time Frame: at baseline and 8 months after baseline
Using the Griffiths Mental Development Scales for China (GDS-C). Gross and fine motor, personal-social-emotional, language and communication and learning development will be assessed
at baseline and 8 months after baseline
Children attention
Time Frame: at baseline and 8 months after baseline
Using an established eye tracking protocol in Chinese pediatric population (using the Tobii TX300 eye tracker)
at baseline and 8 months after baseline
Children behavior (for infants)
Time Frame: at baseline and 8 months after baseline
Using the Infant Behavior Questionnaire (IBQ) for age 3-12 months
at baseline and 8 months after baseline
Children behavior (for toddlers)
Time Frame: at baseline and 8 months after baseline
Using the Early Childhood Behavioral Questionnaire (ECBQ) for age 13 - 36 months
at baseline and 8 months after baseline
Sleep quality
Time Frame: at baseline and 8 months after baseline
Sleep quality, duration and efficiency (total sleep time / duration of sleep episode *100) computed using the Brief Infant Sleep Questionnaire (BISQ). In addition, an actigraphy in combination with a sleep diary will be used during home period and their relationship will indicate the sleep quality
at baseline and 8 months after baseline
Fecal microbiota composition
Time Frame: at baseline and 8 months after baseline
Measured via the shotgun metagenomics sequencing for species composition and functional pathways through stool samples collected
at baseline and 8 months after baseline
Breast milk composition
Time Frame: at baseline and 8 months after baseline
Breast milk composition (lipids, carbohydrates, proteins, minerals and vitamins) will be measured by the MIRIS analyzer through breast milk samples collected (only for breast-fed subjects)
at baseline and 8 months after baseline
Feeding practice
Time Frame: at baseline and 8 months after baseline
Using validated Child Feeding Practice Questionnaire. In addition, to complete the feeding and adverse events calendar monthly during home period
at baseline and 8 months after baseline
Cognitive flexibility
Time Frame: at 36 months of age
Using the Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P) and the Dimensional Change Card Sort (DCCS) task
at 36 months of age
Home environment
Time Frame: at baseline and 8 months after baseline
Using Home Environment questionnaire to collect information on household: siblings, and whether parents receive help on feeding the child.
at baseline and 8 months after baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anthropometry (weight in grams)
Time Frame: at baseline and 8 month after baseline
Weight in grams and corresponding weight-for-age Z-score according to the WHO growth standards
at baseline and 8 month after baseline
Anthropometry (body length in centimeters)
Time Frame: at baseline and 8 month after baseline
Length in centimeters and corresponding length-for-age Z-score according to the WHO growth standards
at baseline and 8 month after baseline
Anthropometry (weight-for-length)
Time Frame: at baseline and 8 month after baseline
Corresponding weight-for-length Z-score according to the WHO growth standards
at baseline and 8 month after baseline
Anthropometry (head circumference in centimeters)
Time Frame: at baseline and 8 month after baseline
Head circumference in centimeters and corresponding head-circumference-for-age Z-score according to the WHO growth standards
at baseline and 8 month after baseline
Anthropometry (BMI)
Time Frame: at baseline and 8 month after baseline
Weight and height will be combined to report the BMI (kg/m2) and corresponding BMI-for-age Z-score according to the WHO growth standards
at baseline and 8 month after baseline
Gastrointestinal tolerance (for infants)
Time Frame: at baseline and 8 month after baseline
using validated Infant Gastrointestinal Symptom Questionnaire (IGSQ) for age 1.5-12 months
at baseline and 8 month after baseline
Gastrointestinal tolerance (for toddlers)
Time Frame: at baseline and 8 month after baseline
using the Toddler Gut Comfort Questionnaire (TGCQ) for age 12-24 months
at baseline and 8 month after baseline
Adverse Events (e.g., type, incidence, severity, seriousness)
Time Frame: from enrollment until 36 months of age
standard AE reporting procedure
from enrollment until 36 months of age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fan Jiang, Shanghai Children's Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2023

Primary Completion (Estimated)

February 1, 2025

Study Completion (Estimated)

March 1, 2025

Study Registration Dates

First Submitted

October 29, 2020

First Submitted That Met QC Criteria

June 3, 2021

First Posted (Actual)

June 7, 2021

Study Record Updates

Last Update Posted (Actual)

October 4, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 20.02.INF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain

Clinical Trials on MRI

3
Subscribe